
- ONCOLOGY Vol 14 No 5
- Volume 14
- Issue 5
Bill Will Allow Doctors to Negotiate Jointly With HMOs
The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against
The House Judiciary Committee overwhelmingly approved what has been a controversial bill (H.R. 1304) allowing independent physicians in a given community to negotiate jointly with a managed care plan. Doing so is currently against antitrust law. But H.R. 1304, which passed by a vote of 26-2, would provide an exemption that has been sought by nearly every medical provider group, including the AMA, in Washington. Sponsored by Rep. Tom Campbell (R-CA), the bill is opposed by the managed care industry and the Clinton administration, both of which claim that it will enable physicians to greatly increase their fees. Antitrust exemptions are intended to augment providers incomes, argues Chip Kahn, president of the Health Insurance Association of America (HIAA). But Donald J. Palmisano, MD, an AMA trustee, argues that managed care plans have too much market power over physicians. The role of physician as patient advocate can be easily undermined when a physician has no leverage in the face of a large, controlling health plan, states Palmisano. Nearly a majority of House members are cosponsors of H.R. 1304, the House should pass it. Prospects for Senate approval are good, too.
Articles in this issue
over 25 years ago
Medicare Rethinking Its Policy on Self-Injectablesover 25 years ago
Home Counseling Program for Women With Lung Cancer to Be Studiedover 25 years ago
New Indication Sought for Bicalutamideover 25 years ago
Approval of Antibody-Targeted Chemotherapy Recommendedover 25 years ago
First Comparison of Anastrozole vs Tamoxifenover 25 years ago
FDA Approves Irinotecan as First-Line Therapy for Colorectal Cancerover 25 years ago
Understanding Leukaemia and Related Cancersover 25 years ago
New Drug for Refractory Cutaneous T-Cell LymphomaNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.